Michael Boutros
9Patents
1h-index
19Co-inventors
44Inventor score
Filing activity: Jun 25, 2010 → Sep 6, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8629272B2 | Tricyclic pyrimidine derivatives as wnt antagonists | Human Necessities | 42 | Active |
| US9970938B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | Physics | 1 | Active |
| US9994854B2 | Cytotoxic T cell response modifiers | Physics | 0 | Active |
| US10222377B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | Physics | 0 | Active |
| US9371333B2 | Chromene derivatives and their analoga as Wnt pathway antagonists | Chemistry; Metallurgy | 0 | Active |
| US10065939B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | Chemistry; Metallurgy | 0 | Active |
| US11802285B2 | Cytotoxic T cell response modifiers | Physics | 0 | Active |
| US12338440B2 | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US9062114B2 | Gpr177 as target and marker in tumors | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.